![Avastin as effective as Eylea for treating central retinal vein occlusion | National Institutes of Health (NIH) Avastin as effective as Eylea for treating central retinal vein occlusion | National Institutes of Health (NIH)](https://www.nih.gov/sites/default/files/styles/featured_media_breakpoint-medium/public/news-events/news-releases/2017/20170509-retina.jpg?itok=P_qEQcT1×tamp=1494343971)
Avastin as effective as Eylea for treating central retinal vein occlusion | National Institutes of Health (NIH)
![IJTM | Free Full-Text | Heparin–Avastin Complexes Show Enhanced VEGF Binding and Inhibition of VEGF-Mediated Cell Migration IJTM | Free Full-Text | Heparin–Avastin Complexes Show Enhanced VEGF Binding and Inhibition of VEGF-Mediated Cell Migration](https://www.mdpi.com/ijtm/ijtm-01-00008/article_deploy/html/images/ijtm-01-00008-g001.png)
IJTM | Free Full-Text | Heparin–Avastin Complexes Show Enhanced VEGF Binding and Inhibition of VEGF-Mediated Cell Migration
![Benefits & Risks of treatment for persistent, recurrent, or metastatic Cervical Cancer (CC) | Avastin® (bevacizumab) Benefits & Risks of treatment for persistent, recurrent, or metastatic Cervical Cancer (CC) | Avastin® (bevacizumab)](https://www.avastin.com/content/dam/gene/avastin/patient/images/mobile/cc/Side-effects-of-Avastin-CC-Mobile.genecoreimg.480.png)
Benefits & Risks of treatment for persistent, recurrent, or metastatic Cervical Cancer (CC) | Avastin® (bevacizumab)
![Systemic Bevacizumab Treatment for Recurrent Respiratory Papillomatosis: Long‐Term Follow‐Up - Ruiz - 2022 - The Laryngoscope - Wiley Online Library Systemic Bevacizumab Treatment for Recurrent Respiratory Papillomatosis: Long‐Term Follow‐Up - Ruiz - 2022 - The Laryngoscope - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/15579c2d-e3db-41ab-9e8e-b4ccf866ffae/lary.v132.10.cover.jpg?trick=1681410801542)
Systemic Bevacizumab Treatment for Recurrent Respiratory Papillomatosis: Long‐Term Follow‐Up - Ruiz - 2022 - The Laryngoscope - Wiley Online Library
![Frontiers | Combined Therapy With Avastin, a PAF Receptor Antagonist and a Lipid Mediator Inhibited Glioblastoma Tumor Growth Frontiers | Combined Therapy With Avastin, a PAF Receptor Antagonist and a Lipid Mediator Inhibited Glioblastoma Tumor Growth](https://www.frontiersin.org/files/MyHome%20Article%20Library/746470/746470_Thumb_400.jpg)
Frontiers | Combined Therapy With Avastin, a PAF Receptor Antagonist and a Lipid Mediator Inhibited Glioblastoma Tumor Growth
TECENTRIQ® (atezolizumab) + Avastin® (bevacizumab): The first and only cancer immunotherapy combination in 1L unresectable or mHCC
![Benefits & risks of treatment for 1L metastatic non-squamous non-small cell lung cancer (NSCLC) | Avastin® (bevacizumab) Benefits & risks of treatment for 1L metastatic non-squamous non-small cell lung cancer (NSCLC) | Avastin® (bevacizumab)](https://www.avastin.com/content/dam/gene/avastin/patient/images/mobile/nsclc/Life-threatening-side-effects-of-Avastin-NSCLC-Mobile.genecoreimg.480.png)
Benefits & risks of treatment for 1L metastatic non-squamous non-small cell lung cancer (NSCLC) | Avastin® (bevacizumab)
![Frontiers | Incidence and Risk of Hypertension in Cancer Patients Treated With Atezolizumab and Bevacizumab: A Systematic Review and Meta-Analysis Frontiers | Incidence and Risk of Hypertension in Cancer Patients Treated With Atezolizumab and Bevacizumab: A Systematic Review and Meta-Analysis](https://www.frontiersin.org/files/Articles/726008/fonc-11-726008-HTML-r1/image_m/fonc-11-726008-g001.jpg)